Galderma, a leading medical aesthetics company, has announced the launch of Restylane® VOLYME™, a hyaluronic acid injectable filler, in China. This product is specifically designed for contouring and volumizing the mid-face region, helping patients achieve a revitalized and more youthful appearance. In addition to Restylane® VOLYME™, Galderma is also introducing its complementary treatment called Shape Up Holistic Individualized Treatment (HIT™), which addresses aging concerns in the mid-face caused by the loss of structural support.
The aesthetics medicine market in China has experienced significant growth in the past decade. With low market penetration, there is still great potential for future growth and demand for innovative solutions. Restylane® VOLYME™, developed using Galderma’s proprietary OBT™ gel technology, has been proven to effectively correct mid-face volume deficit and contour deficiencies through subcutaneous injections.
Hyaluronic acid fillers, like Restylane® VOLYME™, have become increasingly popular among patients seeking mid-face augmentation. They offer high patient satisfaction and deliver long-lasting results. In fact, hyaluronic acid fillers are among the top 10 most-sold aesthetics products in China.
The introduction of Shape Up HIT™ in China further enhances Galderma’s commitment to meeting the needs of both patients and injectors. This individualized treatment approach allows practitioners to optimize aesthetic outcomes while prioritizing patient satisfaction. The Shape Up HIT™ encourages a two-way dialogue between patients and practitioners, ensuring that patient priorities are aligned and that natural facial expressions are maintained.
Galderma is dedicated to delivering its full range of aesthetics products to China and other countries around the world. By collaborating with research and development teams, local partners, and regulatory authorities, Galderma aims to provide innovative solutions that meet the varied and individual needs of patients and injectors.
With over 65 million treatments administered worldwide, Restylane® is the largest and most diverse range of hyaluronic acid fillers on the market. Galderma, as a leading player in the dermatology industry, is committed to advancing dermatology and meeting the unique needs of every individual, shaping their skin stories.
References:
– Deloitte. China Aesthetic Medicine Outlook Report.
– Talarico S et al. High patient satisfaction of a hyaluronic acid filler producing enduring full-facial volume restoration: An 18-month open multicenter study.
– Galderma. Restylane Instructions for Use.
– Trinh LN & Gupta A. Hyaluronic acid fillers for midface augmentation: A systematic review.
– Öhrlund A. New method to study the balance of firmness and flexibility for HA fillers.
– Galderma. Data on file.
Galderma’s introduction of Restylane® VOLYME™ and Shape Up HIT™ to China’s aesthetics market comes at a time of significant growth in the aesthetics medicine industry in China. The market still has low market penetration, indicating the potential for further growth and demand for innovative solutions in the coming years. (Deloitte)
Restylane® VOLYME™ is a hyaluronic acid injectable filler specifically designed for contouring and volumizing the mid-face region, offering patients a revitalized and more youthful appearance. The product has been developed using Galderma’s proprietary OBT™ gel technology, which has been proven to effectively correct mid-face volume deficit and contour deficiencies through subcutaneous injections. (Galderma)
Hyaluronic acid fillers, such as Restylane® VOLYME™, have gained popularity among patients seeking mid-face augmentation. These fillers offer high patient satisfaction and deliver long-lasting results. In fact, hyaluronic acid fillers are among the top 10 most-sold aesthetics products in China. (Talarico et al.)
Shape Up HIT™, Galderma’s complementary treatment to Restylane® VOLYME™, addresses aging concerns in the mid-face caused by the loss of structural support. This individualized treatment approach allows practitioners to optimize aesthetic outcomes while prioritizing patient satisfaction. The Shape Up HIT™ promotes a two-way dialogue between patients and practitioners, ensuring that patient priorities are aligned and that natural facial expressions are maintained. (Galderma)
Galderma is committed to meeting the needs of both patients and injectors by delivering its full range of aesthetics products to China and other countries around the world. The company collaborates with research and development teams, local partners, and regulatory authorities to provide innovative solutions that cater to the varied and individual needs of patients and injectors. (Galderma)
Advantages of Restylane® VOLYME™ and Shape Up HIT™ include their ability to effectively address mid-face volume deficit and contour deficiencies, providing patients with a rejuvenated appearance and high satisfaction. The individualized treatment approach of Shape Up HIT™ ensures patient priorities are considered, leading to natural-looking results. Galderma’s commitment to research and collaboration allows for the development of innovative solutions that meet the diverse needs of patients and injectors. (Talarico et al., Galderma)
However, it is important to note that the aesthetics medicine market in China also poses challenges and controversies. Some key challenges include the need for increased awareness and education among both patients and practitioners about the available treatment options and their potential risks. There may also be concerns about the affordability of these treatments for all segments of the population. (Deloitte)
In summary, Galderma’s introduction of Restylane® VOLYME™ and Shape Up HIT™ to China’s aesthetics market comes at a time of significant growth in the industry. These products offer effective solutions for mid-face volume deficit and contour deficiencies, leading to high patient satisfaction. However, challenges such as awareness, education, and affordability need to be addressed to fully tap into the market’s potential.